-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] April 15 to April 21, 2022 is the 28th "National Cancer Prevention and Control Publicity Week", and the theme of this year's publicity week is "Cancer Prevention and Control Early Action"
.
Breast cancer is one of the common gynecological malignancies, which seriously threatens women's health
.
In recent years, with the increase of emotional, life and work pressure, as well as irregular work and rest and unhealthy diet, the risk of breast cancer in young women has been increasing
.
According to new data released by the World Health Organization, there are about 420,000 new breast cancer patients in China every year, and the incidence rate is increasing by 3% to 4% every year
.
For breast cancer, early prevention is the key
.
Industry insiders emphasize that the prevention and treatment of breast cancer requires three "early steps", namely, early screening, early diagnosis, and early treatment
.
Among them, in terms of early screening and early diagnosis, a relatively individualized screening plan can be implemented according to different risk groups.
If there are known gene mutations, known family history or known history of breast dysplasia, they belong to high-risk groups and should be checked regularly.
The frequency of examinations can be twice a year; while healthy women can be examined once every two years
.
Breast cancer treatment has also received much attention from the industry
.
In recent years, with the continuous exploration of breast cancer treatment drugs by the medical community, new breast cancer drugs have been born, and more research and development drugs are on the way
.
It is understood that HER2-positive breast cancer accounts for more than 20% of all breast cancers, and has the characteristics of high malignancy, rapid disease progression, and easy metastasis
.
In recent years, with the continuous development and application of anti-HER2 drugs, the treatment of HER2-positive breast cancer patients has been improved to some extent
.
According to the industry, currently domestic HER2-positive advanced breast cancer can use Pertuzumab combined with trastuzumab dual-target regimen, or Pertuzumab + Trastuzumab + chemotherapy, or you can choose second-line pyrrole tinib + capecitabine or trastuzumab (T-DM1)
.
In addition, the application prospect of DS-8201, which will be listed in China, is also optimistic in the industry
.
Recent relevant trial results show that DS-8201 shows greater advantages in second-line and TDM1 head-to-head comparisons, and the product can be used to treat unresectable or metastatic disease that has received two or more anti-HER2 regimens in the past.
Adult patients with HER2-positive breast cancer
.
It is also currently recommended as a second-line treatment for advanced HER2
.
It is worth mentioning that breast cancer is complex and difficult to treat and requires long-term medication, and patients generally face a heavy cost burden
.
In order to reduce the cost pressure of patients, in recent years, batches of new breast cancer drugs have also been reduced in price into medical insurance, or companies have taken the initiative to reduce prices, so that breast cancer patients will no longer "smell it"
.
For example, in December 2021, Eli Lilly's new breast cancer drug CDK4/6 inhibitor Abecili tablets was included in the new version of the National Medical Insurance List, and the price dropped by about half
.
In March of this year, Roche announced to reduce the price of the breast cancer drug Enmet trastuzumab by up to 52%, of which the 100mg/bottle dosage form dropped from 19,282.
00 yuan to 9,200 yuan, and the 160mg/bottle dosage form dropped from 27,632.
04 yuan to 13,184.
05 yuan.
The large price cut of this drug will further reduce the burden on the majority of breast cancer patients in China
.
Previously, Pfizer’s new breast cancer drug Aiboxin also made a decision to reduce the price by 54% because it was not covered by medical insurance, and the price per bottle dropped from 29,799 yuan to 13,667 yuan
.
At the same time, Pfizer also adjusted its patient assistance program, phasing out charitable drug donations for low-income and low-income patients
.
From the perspective of the industry, behind the price cuts of multinational pharmaceutical companies, the price war for breast cancer drugs has actually started
.
At present, a large number of domestic pharmaceutical companies such as Hengrui, Sihuan Pharmaceutical, and Luye Pharmaceutical have entered the field of breast cancer treatment.
The market competition is already very fierce.
In the future, regardless of whether imported drugs or domestic drugs, price reduction will become a trend
.
For patients, under the background of the advent of new drugs and the price reduction of drugs, it means that breast cancer treatment has accelerated into a new era! Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Breast cancer is one of the common gynecological malignancies, which seriously threatens women's health
.
In recent years, with the increase of emotional, life and work pressure, as well as irregular work and rest and unhealthy diet, the risk of breast cancer in young women has been increasing
.
According to new data released by the World Health Organization, there are about 420,000 new breast cancer patients in China every year, and the incidence rate is increasing by 3% to 4% every year
.
For breast cancer, early prevention is the key
.
Industry insiders emphasize that the prevention and treatment of breast cancer requires three "early steps", namely, early screening, early diagnosis, and early treatment
.
Among them, in terms of early screening and early diagnosis, a relatively individualized screening plan can be implemented according to different risk groups.
If there are known gene mutations, known family history or known history of breast dysplasia, they belong to high-risk groups and should be checked regularly.
The frequency of examinations can be twice a year; while healthy women can be examined once every two years
.
Breast cancer treatment has also received much attention from the industry
.
In recent years, with the continuous exploration of breast cancer treatment drugs by the medical community, new breast cancer drugs have been born, and more research and development drugs are on the way
.
It is understood that HER2-positive breast cancer accounts for more than 20% of all breast cancers, and has the characteristics of high malignancy, rapid disease progression, and easy metastasis
.
In recent years, with the continuous development and application of anti-HER2 drugs, the treatment of HER2-positive breast cancer patients has been improved to some extent
.
According to the industry, currently domestic HER2-positive advanced breast cancer can use Pertuzumab combined with trastuzumab dual-target regimen, or Pertuzumab + Trastuzumab + chemotherapy, or you can choose second-line pyrrole tinib + capecitabine or trastuzumab (T-DM1)
.
In addition, the application prospect of DS-8201, which will be listed in China, is also optimistic in the industry
.
Recent relevant trial results show that DS-8201 shows greater advantages in second-line and TDM1 head-to-head comparisons, and the product can be used to treat unresectable or metastatic disease that has received two or more anti-HER2 regimens in the past.
Adult patients with HER2-positive breast cancer
.
It is also currently recommended as a second-line treatment for advanced HER2
.
It is worth mentioning that breast cancer is complex and difficult to treat and requires long-term medication, and patients generally face a heavy cost burden
.
In order to reduce the cost pressure of patients, in recent years, batches of new breast cancer drugs have also been reduced in price into medical insurance, or companies have taken the initiative to reduce prices, so that breast cancer patients will no longer "smell it"
.
For example, in December 2021, Eli Lilly's new breast cancer drug CDK4/6 inhibitor Abecili tablets was included in the new version of the National Medical Insurance List, and the price dropped by about half
.
In March of this year, Roche announced to reduce the price of the breast cancer drug Enmet trastuzumab by up to 52%, of which the 100mg/bottle dosage form dropped from 19,282.
00 yuan to 9,200 yuan, and the 160mg/bottle dosage form dropped from 27,632.
04 yuan to 13,184.
05 yuan.
The large price cut of this drug will further reduce the burden on the majority of breast cancer patients in China
.
Previously, Pfizer’s new breast cancer drug Aiboxin also made a decision to reduce the price by 54% because it was not covered by medical insurance, and the price per bottle dropped from 29,799 yuan to 13,667 yuan
.
At the same time, Pfizer also adjusted its patient assistance program, phasing out charitable drug donations for low-income and low-income patients
.
From the perspective of the industry, behind the price cuts of multinational pharmaceutical companies, the price war for breast cancer drugs has actually started
.
At present, a large number of domestic pharmaceutical companies such as Hengrui, Sihuan Pharmaceutical, and Luye Pharmaceutical have entered the field of breast cancer treatment.
The market competition is already very fierce.
In the future, regardless of whether imported drugs or domestic drugs, price reduction will become a trend
.
For patients, under the background of the advent of new drugs and the price reduction of drugs, it means that breast cancer treatment has accelerated into a new era! Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
